Clinical Trials Logo
  1. Home
  2. Neurotrophic Keratitis
  3. NCT03037450

Miniinvasive Corneal Neurotization. A Pilot Study. — MICORNE  

Neurotrophic Keratitis Clinical Trial

Official title:
Miniinvasive Corneal Neurotization. A Pilot Study.

Clinical Trial Summary

Neurotrophic keratitis (NK) is a degenerative disease of the cornea due to the impairment of the nasociliary branch of the ophthalmic nerve. Reduced corneal sensation lead to several corneal lesions including spontaneous ulcerations, delayed wound healing, corneal scarring, neovascularization, thinning, perforation or infection. An important and permanent visual loss of is frequently associated with the condition. NK can be congenital or acquired. Its acquired forms can be due to traumatic, infectious (herpes, zoster), neoplastic or iatrogenic causes. There is currently no specific medical treatment. Surgical reconstruction techniques of sensory neurotizations have recently been described in young patients suffering traumatic, congenital or neoplastic NK using supratrochlear nerves as the sensory donor nerves and sural nerve as healthy graft. A neurotization involves the transfer of a healthy donor nerve segment into a tissue to reestablish either motor or sensory innervation. The aim of the present study is to assess the outcomes of a novel sensory neurotization technique for the treatment of severe NK in adult patients (Stages 2 and 3 of Mackie classification). Corneal neurotizations will be performed using either ipsilateral supraorbital nerve as donor nerve (direct neurotization) or contralateral supraorbital nerve as donor nerve and a segment of the lateral antebrachial cutaneous nerve as graft. Small-size skin incisions (less than 3 centimeters) will be made in one or both eyebrow and an endoscopic device will help the surgeons to localize and dissect the supraorbital nerve. Donor nerves or graft will be sutured to the neurotrophic corneas. Adult patients with unilateral NK due to infectious, traumatic or iatrogenic causes will be included.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03037450
Study type Interventional
Source University Hospital, Strasbourg, France
Contact
Status Terminated
Phase N/A
Start date June 1, 2017
Completion date January 22, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04485546 - Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis Phase 4
Not yet recruiting NCT05927428 - Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis Phase 2
Completed NCT04552730 - Nerve Growth Factor for the Treatment of Cornea Disease
Completed NCT04276558 - REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients Phase 2
Recruiting NCT04573647 - OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
Completed NCT04820010 - Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Recruiting NCT04627571 - Corneal Nerves After Treatment With Cenegermin
Enrolling by invitation NCT05758753 - QST for Corneal Nerve Function N/A
Terminated NCT05809245 - Corneal Neurotization as a Treatment for Neurotrophic Keratopathy N/A
Withdrawn NCT05321251 - Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy. Phase 2/Phase 3
Not yet recruiting NCT06364657 - Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
Recruiting NCT05566717 - An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Not yet recruiting NCT02707120 - Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis Phase 4
Completed NCT01756456 - Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. Phase 1/Phase 2
Completed NCT02227147 - Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK Phase 2
Recruiting NCT05552261 - DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Recruiting NCT04909450 - Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects Phase 1/Phase 2
Active, not recruiting NCT06411145 - Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis Phase 4